Pfizer Inc. (PFE.US) welcomes a dawn of recovery! New drug revenue surges by 18%, but the patent cliff remains the biggest challenge.

After a continued decline in revenue from COVID-related products, Pfizer Inc. (PFE.US) has begun to show signs of more stable growth. The pharmaceutical giant reported second-quarter revenue for fiscal year 2026 of $15 billion, representing a year-over-year increase of 1% on an operational basis; excluding Comirnaty and Paxlovid, revenue increased by 5% year-over-year on an operational basis. At the same time, the company raised the midpoint of its full-year revenue guidance. Based on the outperformance of non-COVID products, Pfizer Inc. adjusted its full-year revenue guidance for 2026 from the previous $59.5 billion to $62.5 billion, to a new range of $60.5 billion to $62.5 billion, with the new midpoint increased by $500 million. The company also reiterated its full-year adjusted earnings per share guidance of $2.80 to $3.00, which is broadly in line with market expectations of $2.95. However, Pfizer Inc.'s recovery still faces a significant testwhether cost-cutting measures can offset the impact of upcoming patent expirations on several mature drugs. Bullish Reasons One point that makes investors optimistic is that Pfizer Inc. is becoming less dependent on unpredictable COVID-related sales, with its non-COVID product portfolio driving growth. Newly launched drugs and those acquired through mergers and acquisitions generated $3.2 billion in revenue during the quarter, reflecting an 18% increase on an operational basis. The company has also lowered its expectations for COVID-19-related revenue in 2026 to approximately $4 billion, primarily due to weak demand for Paxlovid. The company's growth is also becoming more diversified. Padcev continues to gain market share in the bladder cancer field, while Vyndaqel continues to benefit from increased diagnostics and demand in international markets. Padcev's revenue increased by 23% on an operational basis to $667 million; Vyndaqel products generated $1.76 billion in revenue, reflecting an 8% operational increase. This is significant as the company needs multiple products to support post-pandemic recovery rather than relying solely on one blockbuster drug. Pfizer Inc. has also expanded its cost-saving targets and is on track to achieve a net savings of approximately $5.7 billion by the end of 2026. The company projects that by 2029, cumulative net savings from cost-cutting measures will reach $6.7 billion, helping to offset the decline in COVID-related revenue and restore sustainable growth. These savings are expected to support margins and free up more resources for investment in oncology and obesity, even as revenue growth remains moderate. Bearish Reasons From an operational standpoint, Pfizer Inc.'s revenue grew by just 1%, with currency fluctuations also contributing to growth during the reporting period. This is significant because the company's turnaround has not yet brought strong organic growth across the entire organization. Pfizer Inc. also reported a GAAP pretax loss from continuing operations, partly due to impairment, litigation, restructuring, and acquisition-related costs. Therefore, the reported profitability of the company is still affected by restructuring and costs related to its business portfolio. Another critical issue for investors to watch is the company's patent expirations. Pfizer Inc. anticipates that several patent expirations between 2026 and 2030 will exert significant pressure on revenue, with key products facing competition, including Eliquis, Ibrance, and Xtandi. The company's full-year financial guidance for 2026 indicates that due to several products having recently lost or about to lose patent or regulatory protection, and facing or expected to face competition from generics and biosimilars, this related competition is expected to have an adverse impact of approximately $1.1 billion on revenue. Despite Padcev and Vyndaqel achieving growth, investors currently lack conclusive evidence that Pfizer Inc.'s new product portfolio can replace the total revenue contributions of mature products that will face losses due to upcoming patent expirations. What Do Hedge Funds Think? Hedge fund sentiment provides another perspective on Pfizer Inc.'s future outlook. According to Insider Monkey's database of 1,022 hedge funds, the number of hedge funds holding Pfizer Inc. stock increased slightly from 81 in the fourth quarter of 2025 to 83 in the first quarter of 2026. Although this increase is too small to indicate a decisive shift in institutional investor confidence, it shows that hedge funds' interest has remained stable and slightly positive as Pfizer Inc. continues to work on its turnaround. Conclusion As Pfizer Inc. continues to expand its non-COVID product portfolio, with products like Padcev and Vyndaqel achieving growth, and management consistently reduces the company's cost base, the company's turnaround is becoming increasingly credible. However, this recovery is not yet complete. The company's revenue growth on an operational basis remains moderate, and upcoming patent expirations could impose significant pressure on the revenue streams of several mature product franchises. Pfizer Inc.'s lower cost structure provides some breathing space, but its long-term investment logic ultimately hinges on one crucial question: Can the companys new drugs grow large enough to replace the revenue it is preparing to lose from upcoming expirations?